Almac Picks Rosetta Resolver Over Lower-Priced Options for Array-Based Cancer Dx Development | GenomeWeb

Rosetta Biosoftware said this week that Almac Diagnostics will use its Rosetta Resolver gene expression-analysis platform to help it develop cancer diagnostics based on Affymetrix microarrays.

The agreement underscores Rosetta's strategy to move its software platform closer to the clinic in step with microarray technology, and follows a diagnostic collaboration with Agendia, the developer of the array-based MammaPrint breast cancer recurrence test, that Rosetta announced in October [BioInform 10-10-05].

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.